MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Regeneron Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

616.89 -2.65

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

614.25

Max

640.1

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-423M

918M

Pardavimai

69M

3.8B

P/E

Sektoriaus vid.

16.529

63.778

Pelnas, tenkantis vienai akcijai

12.07

Dividendų pajamingumas

0.56

Pelno marža

24.219

Darbuotojai

15,106

EBITDA

-534M

1.1B

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+54.17% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

0.56%

2.39%

Kitas uždarbis

2025-04-29

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-5B

70B

Ankstesnė atidarymo kaina

619.54

Ankstesnė uždarymo kaina

616.89

Naujienos nuotaikos

By Acuity

41%

59%

143 / 386 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

Regeneron Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-02-04 12:13; UTC

Uždarbis

Regeneron 4Q Revenue Up on Strong Sales of EYLEA HD

2024-07-08 12:00; UTC

Uždarbis

Regeneron Expects Earnings Hit After $24 Million R&D Charge

2025-02-28 12:00; UTC

Svarbiausios naujienos

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

2025-02-04 11:58; UTC

Uždarbis

Regeneron 4Q Rev Up on Strong Sales of EYLEA HD

2025-02-04 11:37; UTC

Uždarbis

Regeneron Pharma Sees 2025 Adjusted R&D $5B-$5.2B >REGN

2025-02-04 11:37; UTC

Uždarbis

Regeneron Pharma Sees 2025 Gross Margin on Net Product Sales 87%-88% >REGN

2025-02-04 11:36; UTC

Uždarbis

Regeneron Pharma Sees 2025 Capital Spending $850M-$975M >REGN

2025-02-04 11:35; UTC

Uždarbis

Regeneron Pharma Declares Initial Quarterly Dividend of 88c >REGN

2025-02-04 11:35; UTC

Uždarbis

Regeneron Pharma 4Q Adj EPS $12.07 >REGN

2025-02-04 11:34; UTC

Uždarbis

Regeneron Pharma 4Q U.S. Net Sales for Eylea HD, Eylea Rose 2% to $1.5B >REGN

2025-02-04 11:34; UTC

Uždarbis

Regeneron Pharma: 4Q Dupixent Global Net Sales Recorded by Sanofi Rose 15% to $3.7B >REGN

2025-02-04 11:32; UTC

Uždarbis

Regeneron Pharma Board OKs Additional $3 Billion Share Repurchase >REGN

2025-02-04 11:31; UTC

Uždarbis

Regeneron Pharma Initiates Quarterly Cash Dividend Program >REGN

2025-01-31 08:30; UTC

Įsigijimai, susijungimai, perėmimai

It's Bananas, but Stock Splits Can Pay Off. Here Are 5 Likely Contenders. -- Barrons.com

2025-01-28 10:30; UTC

Svarbiausios naujienos

Drug Companies Raise Prices on More Than 800 Drugs in January -- WSJ

2024-10-31 13:58; UTC

Uždarbis

Regeneron Takes A Ghastly Turn As High-Dose Eylea Lags And Biosimilars Loom -- IBD

2024-10-31 10:52; UTC

Uždarbis

Regeneron Earnings Top Views For Biotech Giant -- IBD

2024-10-31 10:34; UTC

Uždarbis

Regeneron Pharma 3Q Adj EPS $12.46 >REGN

2024-10-31 10:33; UTC

Uždarbis

Regeneron Pharma 3Q EPS Cut 43c by Acquired IPR&D Charge >REGN

2024-10-31 10:33; UTC

Uždarbis

Regeneron Pharma 3Q U.S. Sales for Eylea HD, Eylea Rose 3% to $1.54B >REGN

2024-10-31 10:32; UTC

Uždarbis

Regeneron Pharma: 3Q Dupixent Global Net Sales Recorded by Sanofi Rose 23% to $3.82B >REGN

2024-10-31 10:30; UTC

Uždarbis

Regeneron Pharma 3Q Rev $3.72B >REGN

2024-10-31 10:30; UTC

Uždarbis

Regeneron Pharma 3Q EPS $11.54 >REGN

2024-10-31 10:30; UTC

Uždarbis

Regeneron Pharma 3Q Net $1.34B >REGN

2024-10-25 20:25; UTC

Uždarbis

Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat -- IBD

2024-08-01 11:50; UTC

Uždarbis

Regeneron Stock Climbs After Strong Second-Quarter Performance -- IBD

2024-08-01 10:37; UTC

Uždarbis

Regeneron Pharma 2Q Adj EPS $11.56 >REGN

2024-08-01 10:30; UTC

Uždarbis

Regeneron Pharma 2Q EPS $12.41 >REGN

2024-08-01 10:30; UTC

Uždarbis

Regeneron Pharma 2Q Net $1.43B >REGN

2024-08-01 10:30; UTC

Uždarbis

Regeneron Pharma 2Q Rev $3.55B >REGN

Akcijų palyginimas

Kainos pokytis

Regeneron Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

54.17% į viršų

12 mėnesių prognozė

Vidutinis 951.25 USD  54.17%

Aukščiausias 1,182 USD

Žemiausias 575 USD

Remiantis 20 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Regeneron Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

20 ratings

16

Pirkti

3

Laikyti

1

Parduoti

Techninis įvertinimas

By Trading Central

629.02 / 662.33Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bearish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

143 / 386 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.